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Bone was reported as a crucial organ for regulating glucose homeostasis. In this study, we found that Phex mutant mice (PUG), 
a model of human X-linked hypophosphatemic rickets (XLH), displayed metabolic abnormality in addition to abnormal phos-
phate homeostasis, skeletal deformity and growth retardation. Glucose tolerance was elevated with enhanced insulin sensitivity 
in PUG, though circulating insulin level decreased. Interestingly, bone mineral density defects and glucose metabolic abnor-
mality were both rescued by adding phosphorus- and calcium-enriched supplements in daily diet. Serum insulin level, glucose 
tolerance and insulin sensitivity showed no differences between PUG and wild-type mice with rescued osteocalcin (OCN) fol-
lowing treatment. Our study suggested that OCN is a potential mediator between mineral homeostasis and glucose metabolism. 
This investigation brings a new perspective on glucose metabolism regulation through skeleton triggered mineral homeostasis 
and provides new clues in clinical therapeutics of potential metabolic disorders in XLH patients.  
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X-linked hypophosphatemic rickets (XLH), also known as 
X-linked vitamin D-resistant rickets, is one of the rachitic 
bone diseases with an incidence rate of about 1 in 20,000 
[1]. Patients with XLH usually show rickets in children and 
osteomalacia in adults. XLH is characterized by growth 
retardation, impaired phosphate reabsorption, affected bone 
mineralization, low level of 1,25-(OH)2D3 and occasionally 
dental abscess [2,3]. Most XLH patients possess various 
mutations on gene Phex [3,4], abbreviated for phosphate 
regulating gene with homologies to endopeptidases on the X 
chromosome, proving the importance of PHEX functions in 
skeletal morphology and mineral homeostasis [5,6].  
In the past decades, bone was studied as an endocrinal 
organ [7,8]. Interactions between bone and energy metabo-
lism aroused extensive interests and concerns [911]. Phex 
is mainly expressed in osteoblasts and odontoblasts [1214] 
and its mutations lead to reduced 1,25-(OH)2D3 and elevat-
ed circulating FGF23 (fibroblast growth factor 23) [1517]. 
1,25-(OH)2D3 and its receptor could influence expression of 
uncoupling protein (UCP) in adipocytes [18,19]. In vitro 
studies demonstrate that the role of 1,25-(OH)2D3 in lipid 
metabolism is regulator of peroxisome proliferator-activated 
receptor alpha (Ppara) [20]. Circulating FGF23 is also as-
sociated with fat mass and serum lipids [21]. In mouse 
models of XLH, like Hyp mice, decreased renal glucose 
reabsorption activity [22], increased glucose production in 
renal proximal tubules [23] and osteoblasts [24] were ob-
served. The only known physiological substrate of PHEX 
protein, acidic serine aspartate-rich MEPE associated motif 
(ASARM peptide), could regulate glucose metabolism and 
insulin signaling [14]. The above findings indicate PHEX- 
mediated association between skeletal function and energy 
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metabolism. 
Furthermore, phosphate homeostasis, destructed in XLH 
patients [25], is also connected to energy metabolism 
[26,27]. Phosphorus contributes to bone development and 
maintenance [28]. Bone regulates energy metabolism 
through modifying expression of relative genes such as os-
teocalcin (Ocn). OCN is produced by osteoblasts and affects 
beta-cell functions. Overexpression of OCN resulted in ab-
errant insulin production and sensitivity [11,29,30]. All the 
reports above imply a mineral homeostasis-mediated corre-
lation between mineral homeostasis, bone functions and 
energy metabolism.  
This study presents a series of novel phenotypes in XLH 
mouse model and provides a new angle of view to study the 
relationship between skeletal deformities and glucose me-
tabolism. We rescue the abnormal bone and glucose metab-
olism via modifying mineral homeostasis. 
1  Materials and methods 
1.1  Mice and diets 
PUG mice were obtained from Model Animal Research 
Center (MARC) of Nanjing University (Nanjing, Jiangsu, 
China). All mice were bred in specific pathogen-free (SPF) 
animal rooms and manipulated according to Animal proto-
col approved by IACUC of MARC. Mice were housed un-
der a normal 12 h light/12 h dark with water and food ad 
libitum. PUG male mice and their wild-type littermates 
were divided into three groups, the first was wild-type mice 
(WT) fed with regular diet (RD, 0.5% Pi and 0.5% Ca), the 
second was PUG fed with RD and the third was PUG fed 
with high Pi/Ca diet (HPD, 2% Pi and 1.1% Ca). All three 
groups were fed with respective diets from ablactation at 
postnatal 21 days.  
1.2  Body weight and body length measurements 
Body weights of all mice were measured once a week at 
5:30 p.m. Whole tail lengths and body lengths were meas-
ured after anesthetization by 2.5% avertin (5 mg per 10 g 
body weight) [31].  
1.3  Bone mineral density (BMD) and X-ray imaging 
Excluding head and tail, lean mass and bone mineral density 
were assessed by dual-energy X-ray absorptiometry (DEXA) 
system (PIXImus 2, GE lunar, USA). X-ray photos were 
taken using Faxitron MS-20 specimen radiography system 
(Faxitron X-ray Corporation, Wheeling, IL, USA) for 12 s 
at 23 kV. All mice were fasted overnight (16 h) and anes-
thetized by 2.5% avertin (5 mg per 10 g body weight) be-
fore measurements. 
1.4  Blood biochemical analysis 
Blood samples were collected from venous sinus of optical 
orbit after overnight fasting. Clot blood samples by standing 
for 2 h on ice and centrifuge them at 3,000×g for 20 min at 
4°C to isolate the serum. Serum was store at 20°C for 
short period and 80°C for long storage. Serum phosphorus 
(Pi), calcium (Ca) and alkaline phosphatase (ALP) were 
detected with the 7600 Clinical Analyzer (Hitachi 
High-Technologies, Japan). 
1.5  Blood glucose, serum insulin and serum osteocalcin 
measurements 
Blood glucose levels were tested in blood samples obtained 
from mice tail tips after fasting from 9:00 a.m. to 5:00 p.m. 
every week using glucocard blood glucose test meter 
(GT-1640, ARKRAY Inc, Japan). Mice blood was collected 
from venous sinus of optical orbit at 9:30 a.m. after fed ad lib 
or fast overnight for serum insulin level detection respec-
tively. Serum insulin and osteocalcin levels were detected 
via RAT/MOUSE INSULIN ELISA KIT (Millipore, USA) 
and Mouse Osteocalcin EIA kit (Biomedical Technologies 
Inc., USA).  
1.6  Glucose tolerance test and insulin tolerance test 
Every two weeks, glucose tolerance test (GTT) or insulin 
tolerance test (ITT) was carried out after 8 and 6 h fasting in 
the daytime respectively. Mice were intraperitoneally in-
jected with D-(+)-glucose (G6152, Sigma, USA; 2 g/kg 
body weight) for GTT and insulin (Novo Nordisk, Tianjing, 
China, 0.5 IU/kg body weight) for ITT. Blood glucose was 
detected from tail tips at 0, 15, 30, 45, 60, 90 and 120 min 
after injection. 
1.7  Statistics 
Statistical analyses were determined using unpaired two- 
tailed student’s t test. All data are expressed as mean±SEM. 
A P-value of less than 0.05 was considered statistically sig-
nificant. * and §, P<0.05; ** and §§, P<0.01; *** and §§§, 
P<0.001. 
2  Results 
2.1  PUG mice show deficient skeletal morphology and 
abnormal mineral homeostasis 
In different disease models of XLH, for instance, Hyp and 
Gy mice, they display a series of rickets associated pheno-
types, such as growth retardation, skeletal anomalies and 
mineral deficiency [2,32]. PUG mice, with a missense mu-
tation on Phex, were reported as a mouse model of XLH 
[33]. To confirm the phenotype, we studied the growth sta-
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tus and skeletal development in PUG firstly. Concerning 
that Phex is located on X chromosome and female mice 
displayed randomized X chromosome inactivation, hemi-
zygous male PUG mice were used for subsequent investiga-
tions.  
PUG show lower body weight than wild-type mice at the 
age of weaning (WT: 18.96±0.24 g; PUG: 15.85±0.26 g) 
(Figure 1A). Contemporary whole body length was meas-
ured (Figure 1B) and PUG displayed shortened skeleton in 
early growth stage (WT: 7.64±0.05 cm; PUG: 5.72±0.06 
cm). Bone mineral density (BMD) was decreased in both 
local (left femur) (WT: 0.072±0.0016 g cm2; PUG: 
0.053±0.0040 g cm2) and systemic (WT: 0.057±0.0007 g 
cm2; PUG: 0.051±0.0010 g cm2) analysis (Figure 1C). 
X-ray images of PUG lying on its side displayed stunted 
stature, shorter bone structure and increased curvature of 
spinal column (Figure 1D). 
Furthermore, we measured circulating inorganic phos-
phorus (Pi), calcium (Ca) and alkaline phosphatase (ALP) 
levels by analyzing serum of 3-week-old mice. We found 
out that PUG show decreased Pi levels (WT: 2.44±0.19 
mmol L1; PUG: 2.05±0.38 mmol L1) (Figure 1E) and in-
creased ALP levels (WT: 385.1±39.6 mmol L1; PUG: 826±  
74.1 mmol L1) (Figure 1F) while Ca levels remain un-
touched (WT: 2.56±0.14 mmol L1; PUG: 2.42±0.15 mmol 
L1) (Figure 1E). All the phenomena above demonstrated 
that PUG exhibited incipient symptoms of hypophos-
phatemic rickets which are consistent with XLH patients. 
2.2  PUG mice display affected glucose metabolism  
Previous research implied aberrant glucose metabolism in 
Phex-deficient mice [2224], thus we examined blood glu-
cose levels in our model. Three-week-old PUG exhibited 
significant lower blood glucose levels than wild-type mice 
after 8 h fasting (WT: 10.16±0.22 mmol L1; PUG: 
7.93±0.45 mmol L1) (Figure 2A), proving imbalanced 
glucose homeostasis and impaired insulin secretion and 
function. We tested serum insulin levels in both fed and 
fasting status at 3 weeks of age. The results showed that 
there was a notable decline in fed insulin levels (WT: 
1.28±0.82 ng mL1; PUG: 0.81±0.44 ng mL1) and a slight 
drop in fasting insulin levels (WT: 0.45±0.13 ng mL1; PUG: 
0.37±0.09 ng mL1) (Figure 2B), suggesting disordered 
glucose metabolism in PUG mice.  
To further investigate the scavenging capacity of blood  
 
 
Figure 1  PUG mice show growth retardation, mineral homeostasis abnormity and bone deformities. (A) Whole body weights and (B) whole body lengths 
of PUG and control mice were measured at 3 weeks of age (PUG, n=5; WT, n=7). C, Both total and left femur BMD of yearling wild-type (n=8) and PUG 
(n=6) mice were measured. D, Bone structures were displayed by whole body X-ray images (sideways) in yearling wild-type and PUG mice. (E) Serum 
levels of inorganic phosphorus (Pi, WT, n=7; PUG, n=9) and calcium (Ca, WT, n=7; PUG, n=5) and (F) serum alkaline phosphatase (ALP, WT, n=7; PUG, 
n=5) were detected at 3 weeks of age. Data are expressed as mean±SEM. *, P<0.05; **, P<0.01; ***, P<0.001. 
362 Zou JH, et al.   Sci China Life Sci   April (2015) Vol.58 No.4 
 
Figure 2  Reduced circulating glucose, insulin levels, improved glucose tolerance and insulin sensitivity in PUG mice. A, After fasting for 8 h from 9:30 
a.m. to 5:30 p.m., blood glucose of PUG and WT were detected at postnatal 3rd week (n=8 per group). B, Blood was collected at 9:30 a.m. and serum was 
isolated for fed status insulin levels detection (WT, n=7; PUG, n=5). Blood was collected at 5:30 p.m. after 8 h fasting to detect serum insulin levels under 
fasting status (WT, n=7; PUG, n=9). C, GTT (2 g kg1 body weight) was performed on 7-week-old WT (n=8) and PUG mice (n=6). D, ITT (0.5 U kg1 body 
weight) was conducted in 10-week-old PUG (n=7) and WT mice (n=8). Blood glucose of each point-in-time was compared to that of initial point (0 min) and 
the results are exhibited as proportions in both GTT and ITT. Data are expressed as mean±SEM. *, P<0.05; **, P<0.01. 
glucose and response to insulin, we performed glucose tol-
erance tests and insulin tolerance tests at 7 and 10 weeks of 
age, respectively. PUG mice showed significantly improved 
glu-  cose tolerance than control mice (Figure 2C). More-
over, lower blood glucose levels after insulin administration 
were observed in PUG mice (Figure 2D). These suggested 
increased ability in disposing of glucose load and enhanced 
insulin sensitivity in PUG mice. Collectively, blood glucose 
clearance capacity and peripheral insulin sensitivity were 
improved in PUG mice compared to even-aged wild-type, 
suggesting altered glucose metabolism correlative to skele-
tal disorder. 
2.3  Bone deformity and imbalanced mineral homeo-
stasis were partially restored after high Pi/Ca diet 
treatment 
Combined inorganic phosphorus and 1,25-(OH)2D3 are used 
as therapeutic regimen to treat XLH patients [34,35]. How-
ever, animal model research and human cases studies have 
demonstrated that XLH carriers are resistant to vitamin D 
therapy [36]. Therefore, we treated 3-week-old PUG with 
high Pi/Ca diet (HPD) containing 2% inorganic phosphorus 
and 1.1% calcium to check whether HPD could rescue re-
tarded growth and defected bone development. Regular diet 
(RD) with 0.5% phosphorus and 0.5% calcium was used as 
control. Calcium was added to keep the balance between 
phosphorus and calcium and to avoid skeletal demineraliza-
tion and mineral deposits in soft tissues [37,38]. 
PUG mice were fed with HPD from the age of 3 weeks, 
with RD fed PUG and WT as controls. Body weights of 
three groups were measured once a week. After 9 weeks of 
HPD treatment, PUG gained significant heavier body 
weight than RD fed PUG (Figure 3A). Osteocalcin (OCN), 
produced and secreted solely by osteoblasts, is used as a 
biochemical marker to represent bone formation [39]. Se-
rum OCN level declines as the age increases [40]. Elevation 
of circulating OCN levels was detected in 3-week-age PUG 
mice (WT: 188.2±11.1 ng mL1; PUG: 250.7±12.6 ng 
mL1), suggesting disordered skeletal development and al-
tered energy metabolism (Figure 3B). After 5 weeks of 
treatment, HPD fed PUG displayed corrected serum oste-
ocalcin (WT RD: 49.8±5.8 ng mL1; PUG RD: 105.5±7.5 
ng mL1; PUG HPD: 56.1±13.7 ng mL1) (Figure 3B). 
Wild-type mice showed no difference in serum OCN level 
before and after HPD treatment (Figure S1 in Supporting 
Information). After applying one year of high Pi/Ca diet, 
PUG acquired improved body length (WT RD: 9.54±0.06 
cm; PUG RD: 7.85±0.15 cm; PUG HPD: 8.83±0.11 cm) 
(Figure 3C). In addition, bone mineral density and lean 
mass displayed notable raise (Figure 3D and E). Circulating 
inorganic phosphorus (Figure 3F) and alkaline phosphatase 
(Figure 3G) were rescued after 2 weeks of HPD treatment 
and kept close to normal levels after long period treatment. 
These results show that skeletal deformity was rescued after 
restored mineral homeostasis through phosphorus and cal-
cium supplementation.
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Figure 3  Pi and Ca supplements partially rescued growth retardation and mineral deficiency of PUG mice. PUG mice were divided into two groups and 
were fed with regular diet (RD) and high Pi/Ca diet (HPD) respectively. Wild-type mice were fed with RD as control. A, Body weights of WT (n=8), RD fed 
PUG (n=7) and HPD fed PUG mice (n=6) were measured once a week during HPD treatment. B, 3-week-old RD fed WT (n=7) and PUG (n=5) were used to 
detect total OCN levels. Six pairs of WT and PUG mice were fed with HPD. RD fed wild-type mice (n=7) were used as control. After 5 weeks of Pi and Ca 
supplementation, total osteocalcin (OCN) levels were detected. (C) Whole body length, (D) bone mineral density of left femur and (E) lean mass were de-
tected in yearling WT (n=8), RD PUG (n=6) and HPD PUG mice (n=4). Blood biochemistry tests were conducted by testing mouse serum to detect circulat-
ing (F) inorganic phosphorus (Pi) and (G) alkaline phosphatase (ALP) levels at 5 weeks of age (WT, n=8; RD PUG, n=8; HPD PUG, n=6) and 1-year-old 
(WT, n=8; RD PUG, n=6; HPD PUG, n=6). Data are expressed as mean±SEM. *, P<0.05; **, P<0.01; ***, P<0.001.  
2.4  Rescued glucose metabolism in high Pi/Ca diet 
treated PUG mice 
We have described affected glucose metabolism in PUG 
mice and demonstrated that mineral supplements prevent 
growth retardation and bone deformity. We inquired about 
whether the altered glucose homeostasis was engendered by 
hypophosphatemia, so we examined fasting insulin levels in 
HPD fed PUG mice. As shown in Figure 4A, serum insulin 
levels returned to normal levels (WT RD: 0.54±0.06 ng 
mL1; PUG RD: 0.39±0.08 ng mL1; PUG HPD: 0.53±0.07 
ng mL1) after 5 weeks of treatment. We performed GTT 
and ITT 2 weeks later. It shows that PUG obtained normal-
ized peripheral insulin sensitivity (Figure 4B) after feeding 
HPD for 7 weeks. Simultaneously, glucose clearance capac-
ity was restored (Figure 4C). The area under curve of GTT 
represented approximate glucose tolerance ability between 
PUG and wild-type mice (WT RD: 253.6±14.6; PUG RD: 
207.6±12.7; PUG HPD: 239.0±13.6) (Figure 4D). The 
above findings together demonstrated that glucose metabo-
lism was rescued after phosphorus and calcium supplemen-
tation and suggested that mineral homeostasis affects glu-
cose homeostasis in skeletal disorder.
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Figure 4  High Pi/Ca diet treated PUG mice show improved insulin production, normalized insulin sensitivity and glucose metabolism. A, Serum insulin 
levels were detected in RD PUG (n=7), HPD PUG (n=6) and control RD WT mice (n=8) after 5 weeks of HPD treatment. B, Insulin sensitivity was tested by 
ITT (0.5 U kg1 body weight) after 7 weeks of treatment. C, Glucose metabolism was detected at the same time (WT, n=8; RD PUG, n=7; HPD PUG, n=4) 
by GTT (2 g kg1 body weight). Blood glucose was compared to initial point (0 min) and the results are demonstrated as proportions in both GTT and ITT. 
Area under curve of GTT (D) was calculated. Data are expressed as mean±SEM. ns stands for P>0.05. * stands for P<0.05 and ** stands for P<0.01 when 
RD PUG was compared with WT. § stands for P<0.05 and §§ stands for P<0.01 when RD PUG was compared with HPD PUG. 
3  Discussion 
Regulation of energy metabolism by bone has long been 
discussed. In this study, phex mutation induced not only 
defected bone development but also altered glucose metab-
olism. We described enhanced glucose tolerance and insulin 
sensitivity associated with bone deformities and disordered 
mineral metabolism for the first time in animal model of 
XLH. In addition, we rescued both skeletal and metabolic 
abnormalities via restoring mineral homeostasis, suggesting 
a close correlation between bone and energy metabolism. 
Normalized glucose cleaning capability and peripheral insu-
lin sensitivity, following restored serum phosphorus level, 
demonstrate that mineral homeostasis plays an important 
role in regulation of glucose metabolism by bone. 
We also discovered decreased blood glucose in XLH 
mouse model. Blood glucose is regulated by G6Pase in the 
liver. Elevated hepatic G6Pase activity brings about en-
hanced glyconeogenesis and glycogenolysis, leading to se-
rum glucose elevation [41]. However, another study report-
ed that glucose-6-phosphatase (G6Pase) activity was in-
creased in both XLH mouse model and phosphate-deprived 
mice [42]. We did not measure G6Pase activity in PUG 
mice. If hepatic G6Pase activity was upregulated, we spec-
ulated the reason might be a feedback effect aiming to re-
verse the abnormal glucose metabolism according to pub-
lished reports [43]. Moreover, blood glucose homeostasis 
could be regulated by other different signaling. Several 
studies show that blood glucose could be modulated by in-
testine G6PC activity [44], glucose transportation [43] and 
glucose uptake [45], resulting in irrelevance between plas-
ma glucose level and hepatic G6Pase activity. In XLH 
mouse model, decreased renal glucose reabsorption activity 
is also considered contributory to the decreased blood glu-
cose [22]. Otherwise the reduced blood glucose of PUG 
mice resulted from abnormal glucose transport and oxida-
tion stimulated by OCN [45].  
Osteocalcin (OCN), which is secreted by the bone, is one 
of the mediators communicating with adipose [46,47]. OCN 
is also used as a biomarker of skeletal development, and 
increased serum OCN level is associated with increased 
bone mineral density during osteoporosis treatment [48,49]. 
However, in our study, elevated OCN levels were accom-
panied by decreased BMD. This result might be attributed 
to retarded growth and deficient glucose metabolism [50,51]. 
Several researches declare that BMD and osteocalcin level 
can be influenced by estrogen, calcium and fat mass, result-
ing in decreased BMD and increased osteocalcin level  
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[52,53]. It may explain the contradiction between BMD 
decline and serum OCN level elevation in PUG mice. 
OCN is also involved in glucose metabolism via increas-
ing adiponectin in mice [54]. Importantly, uncarboxylated 
form of OCN promotes insulin secretion to affect glucose 
metabolism by means of stimulating glucagons-like pep-
tide-1 (GLP-1) [55]. OCN circulation can be attenuated by 
dietary phosphorus supplementation [56], implying func-
tions of phosphorus in regulating OCN secretion and func-
tion. Of note, our work revealed restored OCN levels and 
insulin levels after mineral homeostasis recovery in PUG 
mice, followed by restored glucose tolerance and insulin 
sensitivity. Overall, there may be a mechanism in which 
aberrant phosphate homeostasis aroused by bone dysfunc-
tion regulates glucose metabolism through regulating circu-
lating OCN level.  
Bone is regulated by adipose-secreted leptin which acts 
on the osteoblast endocrine cell to inhibit bone formation 
through hypothalamic and sympathetic nervous system re-
lays [5760]. On the other hand, OCN secretion is facilitat-
ed by bone to regulate adiposity, glucose metabolism, and 
insulin sensitivity in turn [6163]. Ocn-deficient mice exert 
not only mildly increased bone mass but also lessened β-cell 
proliferation, glucose intolerance and insulin resistant phe-
notypes, imitating type II diabetes [29,64]. Correlations 
between circulating OCN levels and β-cell functions or 
glucose metabolism were observed in obese adults and type 
II diabetes patients [65,66], suggesting secretion role of 
skeleton in regulating lipid anabolism and catabolism. Adi-
ponectin secretion was accelerated by OCN [45] while se-
rum OCN level was positively correlated with adiponectin 
receptor 1 (AdipoR1) expression [67], developing a feed- 
back loop between osseous tissue and energy metabolism 
[68,69]. Therefore, OCN elevation in XLH disease is prob-
able to exhibit damaged lipid metabolism. It highlights new 
arenas for potential investigation in skeletal regulation of 
energy metabolism. 
In summary, our findings represent significant progress 
in understanding the mechanism that bone affects energy 
metabolism through regulating mineral homeostasis. OCN 
could be a potential target for rickets and metabolic diseases 
treatment in the future. Though more efforts should be made 
to identify how OCN functions as a mediator between 
PHEX and mineral homeostasis. Additionally, further ex-
ploration is needed to clarify how Phex mutation brings 
about imbalanced phosphorus homeostasis.  
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